Form 8-K - Current report:
SEC Accession No. 0001193125-25-032804
Filing Date
2025-02-24
Accepted
2025-02-24 07:49:05
Documents
13
Period of Report
2025-02-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d935677d8k.htm   iXBRL 8-K 26904
  Complete submission text file 0001193125-25-032804.txt   153889

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA howl-20250219.xsd EX-101.SCH 2859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20250219_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20250219_pre.xml EX-101.PRE 11713
15 EXTRACTED XBRL INSTANCE DOCUMENT d935677d8k_htm.xml XML 3769
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 25654215
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)